Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of bortezomib plus docetaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Forty-eight patients received up to eight 21-day cycles of docetaxel (60–100 mg m−2 on day 1) plus bortezomib (1.0–1.5 mg m−2 on days 1, 4, 8, and 11). Pharmacodynamic and pharmacokinetic analyses were performed in a subset of patients. Five patients experienced DLTs: grade 3 bone pain (n=1) and febrile neutropenia (n=4). The MTD was bortezomib 1.5 mg m−2 plus docetaxel 75 mg m−2. All 48 patients were assessable for safety and efficacy. The most common adverse events were diarrhoea, nausea, alopecia, asthenia, and vomiting. The most common grade 3/4 toxicities were neutropenia (44%), and febrile neutropenia and diarrhoea (each 19%). Overall patient response rate was 29%. Median time to progression was 5.4 months. In patients with confirmed response, median time to response was 1.3 months and median duration of response was 3.2 months. At the MTD, response rate was 38%. Pharmacokinetic characteristics of bortezomib/docetaxel were comparable with single-agent data. Addition of docetaxel appeared not to affect bortezomib inhibition of 20S proteasome activity. Mean alpha-1 acid glycoprotein concentrations increased from baseline at nearly all time points across different bortezomib dose levels. Bortezomib plus docetaxel is an active combination for anthracycline-pretreated advanced/metastatic breast cancer. The safety profile is manageable and consistent with the side effects of the individual agents.

[1]  J. Tariman,et al.  Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. , 2004, Clinical journal of oncology nursing.

[2]  C. Sotiriou,et al.  Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner , 2006, Molecular Cancer Therapeutics.

[3]  P. Elliott,et al.  Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Millikan,et al.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[6]  D. Richel,et al.  Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[8]  G. Morgan,et al.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.

[9]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Gnant,et al.  TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  E. Dees,et al.  The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer , 2002, Breast Cancer Research.

[12]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[13]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Hung-Ming Wang,et al.  A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. , 2006, Japanese journal of clinical oncology.

[15]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[16]  M. Grever,et al.  Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors , 2004, Clinical Cancer Research.

[17]  J. Cusack.  Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. , 2003, Cancer treatment reviews.

[18]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Elliott,et al.  Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts , 2002, Molecular Cancer Therapeutics.

[20]  A. Schneeweiss,et al.  Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study , 2005 .

[21]  D. Agus,et al.  Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer , 2007, Clinical Cancer Research.

[22]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[23]  S. Soignet,et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[25]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Overgaard.  TP53 Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer , 2000, Acta oncologica.

[27]  J. Doroshow,et al.  Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[29]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[30]  B. Mellado,et al.  Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[31]  J. Hainsworth,et al.  Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial , 2006, Cancer investigation.

[32]  R. Govindan,et al.  Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. McConkey,et al.  The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts , 2004 .

[34]  Sunil R Lakhani,et al.  The pathology of familial breast cancer: Immunohistochemistry and molecular analysis , 1999, Breast Cancer Research.

[35]  M. Carducci,et al.  Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Esseltine,et al.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.

[37]  S. Mandrekar,et al.  A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer , 2005, Clinical Cancer Research.

[38]  J. Bergh,et al.  Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. , 1999, European journal of cancer.

[39]  C. Watson,et al.  p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells , 2001, Cell Death and Differentiation.

[40]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  E. Eisenhauer,et al.  The taxoids. Comparative clinical pharmacology and therapeutic potential. , 1998, Drugs.

[42]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[43]  P. Elliott,et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer , 2001, Journal of cellular biochemistry.

[44]  M. Bissery,et al.  Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. , 1995, Anti-cancer drugs.

[45]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  R. Livingston,et al.  Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Herbst,et al.  The proteasome inhibitor PS-341 in cancer therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  D. McConkey,et al.  The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. , 2004, Molecular cancer therapeutics.

[49]  C. Logothetis,et al.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. , 2003, Molecular cancer therapeutics.

[50]  S. Rodenhuis,et al.  Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion , 2000, Cancer Chemotherapy and Pharmacology.

[51]  H. Goldschmidt,et al.  Hematologic Profiles in the Phase 3 APEX Trial. , 2005 .

[52]  C. Antonescu,et al.  A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas , 2005, Cancer.

[53]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[54]  D. Gandara,et al.  Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. , 2003, Lung cancer.

[55]  H. Koeffler,et al.  Proteasome inhibitor PS‐341 down‐regulates prostate‐specific antigen (PSA) and induces growth arrest and apoptosis of androgen‐dependent human prostate cancer LNCaP cells , 2004, Cancer science.

[56]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.